BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
21 Noviembre 2023 - 5:00AM
Business Wire
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a
biotechnology company focusing on high-value and difficult-to-drug
oncology targets, today announced an agreement for BeiGene to
acquire an exclusive global license to an Investigational New Drug
(IND) application-ready oral cyclin-dependent kinase 2 (CDK2)
inhibitor.
“We are committed to developing novel molecules with the
potential to transform the therapeutic landscape for cancer
patients, and this partnership fits well with our strategic focus
on breast cancer as an area with tremendous unmet need for
innovative treatment options,” said Lai Wang, Ph.D., Global Head of
R&D at BeiGene. “This CDK2 inhibitor from ENSEM complements our
internally discovered Phase 1 CDK4 inhibitor, which has the
potential to improve upon current CDK4/6 inhibitors in some breast
cancer patients, and strengthens our early development pipeline in
breast cancer and other solid tumors. We are excited to work with
ENSEM to bring this molecule into the clinic in the near
future.”
Under the terms of the agreement, ENSEM will receive an upfront
payment, and will be eligible for additional payments upon the
achievement of certain development, regulatory, and commercial
milestones, totaling up to $1.33 billion, in addition to tiered
royalties.
“We are pleased to partner with BeiGene on the development of
this differentiated CDK2 inhibitor,” said Shengfang Jin, Ph.D.,
President and Chief Executive Officer at ENSEM. “We believe BeiGene
is the right partner to advance our first IND-ready asset due to
their wealth of expertise in bringing innovative cancer therapies
to patients globally. This partnership validates the capabilities
of ENSEM’s drug discovery and development team and the ability to
rapidly advance potential best-in-class or first-in-class molecules
utilizing our Kinetic Ensemble® platform. We look forward to
progressing our additional pipeline programs to help patients in
need and supporting BeiGene’s important work to take this therapy
into clinical trials.”
About Ensem Therapeutics
ENSEM is a pioneering drug discovery and development company
that leverages its unique Kinetic Ensemble® platform to develop
innovative small molecule precision medicines for oncology. ENSEM
integrates computational and AI deep learning methodologies with
advanced experimental techniques to identify non-obvious binding
pockets and accelerate structure-based drug design, with a focus on
high-value and difficult-to-drug targets.
For more information, please visit www.ensemtx.com, or engage
with us on LinkedIn.
About BeiGene
BeiGene is a global biotechnology company that is discovering
and developing innovative oncology treatments that are more
affordable and accessible to cancer patients worldwide. With a
broad portfolio, we are expediting development of our diverse
pipeline of novel therapeutics through our internal capabilities
and collaborations. We are committed to radically improving access
to medicines for far more patients who need them. Our growing
global team of more than 10,000 colleagues spans five continents,
with administrative offices in Basel, Beijing, and Cambridge, U.S.
To learn more about BeiGene, please visit www.beigene.com and
follow us on LinkedIn and X (formerly known as Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
BeiGene’s ability to develop novel molecules with the potential to
transform the therapeutic landscape for cancer patients; the
ability of ENSEM’s CDK2 inhibitor to complement BeiGene’s CDK4
inhibitor and strengthen BeiGene’s pipeline; whether BeiGene is the
right partner to advance ENSEM’s first IND-ready asset; ENSEM’s
ability to rapidly advance potential best-in-class or
first-in-class molecules; and BeiGene’s plans, commitments,
aspirations, and goals under the heading “About BeiGene.” Actual
results may differ materially from those indicated in the
forward-looking statements as a result of various important
factors, including BeiGene's ability to demonstrate the efficacy
and safety of its drug candidates; the clinical results for its
drug candidates, which may not support further development or
marketing approval; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials and
marketing approval; BeiGene's ability to achieve commercial success
for its marketed medicines and drug candidates, if approved;
BeiGene's ability to obtain and maintain protection of intellectual
property for its medicines and technology; BeiGene's reliance on
third parties to conduct drug development, manufacturing, and other
services; BeiGene’s limited experience in obtaining regulatory
approvals and commercializing pharmaceutical products and its
ability to obtain additional funding for operations and to complete
the development and commercialization of its drug candidates and
achieve and maintain profitability; and the impact of the COVID-19
pandemic on BeiGene’s clinical development, regulatory, commercial,
manufacturing, and other operations, as well as those risks more
fully discussed in the section entitled “Risk Factors” in BeiGene’s
most recent quarterly report on Form 10-Q, as well as discussions
of potential risks, uncertainties, and other important factors in
BeiGene's subsequent filings with the U.S. Securities and Exchange
Commission. All information in this press release is as of the date
of this press release, and BeiGene undertakes no duty to update
such information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231121206541/en/
Investor Liza Heapes +1 857 302-5663 Ir@beigene.com
Media Kyle Blankenship +1 667 351-5176 media@beigene.com
ENSEM Jordyn Tarazi +1 781 790-5200 ext. 101
info@ensemtx.com
BeiGene (NASDAQ:BGNE)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
BeiGene (NASDAQ:BGNE)
Gráfica de Acción Histórica
De May 2023 a May 2024